Univariate and multivariable Cox regression analysis for OS
| . | Univariate HR (95% CI) . | P value . | Multivariable HR (95% CI) . | P value . |
|---|---|---|---|---|
| Age as continuous variable (y) | 1.03 (1.01-1.05) | .003 | - | - |
| Sex (male vs female) | 1.06 (.70-1.60) | .79 | - | - |
| BMI (overweight/obese vs normal) | 2.26 (1.48-3.45) | <.0001 | 2.38 (1.56-3.63) | <.0001 |
| WBC (>30 vs ≤30 × 109/L) | 1.92 (1.29-2.87) | .001 | 1.79 (1.20-2.69) | .005 |
| CNS-2 or CNS-3 vs CNS-1 | 1.55 (0.94-2.55) | .08 | - | - |
| Immunophenotype B- vs T-ALL | 2.52 (1.41-4.53) | .002 | 2.27 (1.26-4.09) | .006 |
| BCR::ABL1 translocation (yes vs no) | 2.40 (1.46-3.94) | .001 | - | - |
| Complex karyotype (yes vs no) | 0.61 (0.15-2.48) | .49 | - | - |
| Hyperdiploid karyotype (yes vs no) | 0.81 (.39-1.67) | .57 | - | - |
| MLL rearrangement (yes vs no) | 1.58 (0.77-3.27) | .22 | - | - |
| Other karyotype abnormality (yes vs no) | 0.81 (0.52-1.26) | .35 | - | - |
| Treatment type (per protocol vs on protocol) | 0.49 (0.27-0.91) | .023 | - | - |
| Treatment protocols (newer vs older) | 0.60 (0.39-0.92) | .019 | - | - |
| Hepatotoxicity, grade 3/4 (yes vs no) | 0.68 (0.45-1.02) | .06 | - | - |
| Hyperglycemia, grade 3/4 (yes vs no) | 1.61 (1.07-2.44) | .023 | - | - |
| Hypertriglyceridemia, grade 3/4 (yes vs no) | 0.33 (0.18-0.60) | <.0001 | 0.33 (0.18-0.61) | <.0001 |
| AlloSCT (as time dependent variable) | 2.04 (1.26-3.30) | .004 | 1.31 (.80-2.14) | .28 |
| . | Univariate HR (95% CI) . | P value . | Multivariable HR (95% CI) . | P value . |
|---|---|---|---|---|
| Age as continuous variable (y) | 1.03 (1.01-1.05) | .003 | - | - |
| Sex (male vs female) | 1.06 (.70-1.60) | .79 | - | - |
| BMI (overweight/obese vs normal) | 2.26 (1.48-3.45) | <.0001 | 2.38 (1.56-3.63) | <.0001 |
| WBC (>30 vs ≤30 × 109/L) | 1.92 (1.29-2.87) | .001 | 1.79 (1.20-2.69) | .005 |
| CNS-2 or CNS-3 vs CNS-1 | 1.55 (0.94-2.55) | .08 | - | - |
| Immunophenotype B- vs T-ALL | 2.52 (1.41-4.53) | .002 | 2.27 (1.26-4.09) | .006 |
| BCR::ABL1 translocation (yes vs no) | 2.40 (1.46-3.94) | .001 | - | - |
| Complex karyotype (yes vs no) | 0.61 (0.15-2.48) | .49 | - | - |
| Hyperdiploid karyotype (yes vs no) | 0.81 (.39-1.67) | .57 | - | - |
| MLL rearrangement (yes vs no) | 1.58 (0.77-3.27) | .22 | - | - |
| Other karyotype abnormality (yes vs no) | 0.81 (0.52-1.26) | .35 | - | - |
| Treatment type (per protocol vs on protocol) | 0.49 (0.27-0.91) | .023 | - | - |
| Treatment protocols (newer vs older) | 0.60 (0.39-0.92) | .019 | - | - |
| Hepatotoxicity, grade 3/4 (yes vs no) | 0.68 (0.45-1.02) | .06 | - | - |
| Hyperglycemia, grade 3/4 (yes vs no) | 1.61 (1.07-2.44) | .023 | - | - |
| Hypertriglyceridemia, grade 3/4 (yes vs no) | 0.33 (0.18-0.60) | <.0001 | 0.33 (0.18-0.61) | <.0001 |
| AlloSCT (as time dependent variable) | 2.04 (1.26-3.30) | .004 | 1.31 (.80-2.14) | .28 |
CNS, central nervous system; MLL, mixed lineage leukemia.